JP4815053B2 - 経口投与の固形投与形態物としてのマイクロエマルション - Google Patents

経口投与の固形投与形態物としてのマイクロエマルション Download PDF

Info

Publication number
JP4815053B2
JP4815053B2 JP2000564596A JP2000564596A JP4815053B2 JP 4815053 B2 JP4815053 B2 JP 4815053B2 JP 2000564596 A JP2000564596 A JP 2000564596A JP 2000564596 A JP2000564596 A JP 2000564596A JP 4815053 B2 JP4815053 B2 JP 4815053B2
Authority
JP
Japan
Prior art keywords
drug
microemulsion
dosage form
solid dosage
magnesium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000564596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522473A (ja
JP2002522473A5 (enExample
Inventor
パサー，エス．，インディラン
ガプテ，サンギータ，ヴィー．
カーンカリ，ラジェンドゥラ，ケイ．
ホンツ，ジョン
カンベイル，ラムヤ
Original Assignee
シーマ・ラブス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーマ・ラブス、インコーポレイテッド filed Critical シーマ・ラブス、インコーポレイテッド
Publication of JP2002522473A publication Critical patent/JP2002522473A/ja
Publication of JP2002522473A5 publication Critical patent/JP2002522473A5/ja
Application granted granted Critical
Publication of JP4815053B2 publication Critical patent/JP4815053B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000564596A 1998-08-13 1999-08-13 経口投与の固形投与形態物としてのマイクロエマルション Expired - Fee Related JP4815053B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9634798P 1998-08-13 1998-08-13
US60/096,347 1998-08-13
PCT/US1999/018552 WO2000009093A1 (en) 1998-08-13 1999-08-13 Microemulsions as solid dosage forms for oral administration

Publications (3)

Publication Number Publication Date
JP2002522473A JP2002522473A (ja) 2002-07-23
JP2002522473A5 JP2002522473A5 (enExample) 2006-09-28
JP4815053B2 true JP4815053B2 (ja) 2011-11-16

Family

ID=22256941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000564596A Expired - Fee Related JP4815053B2 (ja) 1998-08-13 1999-08-13 経口投与の固形投与形態物としてのマイクロエマルション

Country Status (9)

Country Link
US (1) US6280770B1 (enExample)
EP (2) EP1104290B1 (enExample)
JP (1) JP4815053B2 (enExample)
AT (1) ATE462417T1 (enExample)
AU (1) AU5486899A (enExample)
CA (1) CA2339991C (enExample)
DE (1) DE69942205D1 (enExample)
ES (1) ES2341510T3 (enExample)
WO (1) WO2000009093A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
EP1318790A4 (en) * 2000-09-19 2006-02-01 Cima Labs Inc PHARMACEUTICAL COMPOSITIONS FOR RECTAL AND VAGINAL ADMINISTRATION
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
JP5684440B2 (ja) * 2001-02-23 2015-03-11 シーマ・ラブス、インコーポレイテッド 組成物および固形製剤
CA2448825C (en) * 2001-06-22 2009-08-11 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
ITMI20011756A1 (it) * 2001-08-09 2003-02-09 Remedia S R L Composizione farmaceutica comprendente una microemulsione doppia acqua/olio/acqua incorporata in un supporto solido
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
ITMI20012694A1 (it) * 2001-12-19 2003-06-19 Remedia S R L Composizione farmaceutica comprendente una microemulsione doppia olio/acqua/olio incorporata in un supporto solido
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
WO2004002443A1 (en) * 2002-06-26 2004-01-08 Tuo Jin Solid dosage forms for rapid dissolution of poorly soluble drugs
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
KR20130116378A (ko) * 2004-02-17 2013-10-23 트랜스셉트 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의 사용 방법
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
CA2578356C (en) 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
RU2623206C2 (ru) 2005-04-15 2017-06-22 Кларус Терапьютикс, Инк. Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
JP5050322B2 (ja) * 2005-06-21 2012-10-17 三菱化学株式会社 含油固形物およびその製造方法
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2079450A2 (en) * 2006-11-08 2009-07-22 Novavax, INC. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008091592A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20090060993A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use
EP2111854A1 (en) 2008-04-22 2009-10-28 Lek Pharmaceuticals D.D. Self-microemulsifying systems incorporated into liquid core microcapsules
CA2735660C (en) * 2008-09-09 2017-05-30 Cima Labs Inc. Dosage forms for weakly ionizable compounds
WO2010077878A1 (en) * 2008-12-15 2010-07-08 Fleming And Company, Pharmaceuticals Rapidly dissolving vitamin formulation and methods of using the same
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
PE20120858A1 (es) * 2009-06-11 2012-08-01 Photocure Asa Composiciones solidas que comprenden acido 5-aminolevulinico
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20170325481A1 (en) * 2011-06-28 2017-11-16 Kemin Industries, Inc. Method of forming encapsulated compositions with enhanced solubility and stability
US20130004619A1 (en) * 2011-06-28 2013-01-03 Kemin Industries, Inc. Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability
CA2886276A1 (en) 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
CA2931086C (en) 2012-12-20 2020-11-03 Solural Pharma ApS Solid oral dosage form of testosterone derivative
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
DK3157508T3 (da) * 2014-06-19 2021-02-15 Solural Pharma ApS Fast oral doseringsform af lipofile forbindelser
EP3185872B1 (en) * 2014-08-28 2021-03-31 Board of Regents, The University of Texas System Formulations of testosterone and methods of treatment therewith
WO2016191744A1 (en) 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
ITUA20164228A1 (it) * 2016-06-09 2017-12-09 Labomar S R L Formulazione a matrice grassa auto-emulsionante e gastro-resistente e relativo metodo di preparazione
ES2899037T3 (es) * 2016-08-22 2022-03-09 Remediation Products Inc Composición de biorremediación con materiales de liberación en el tiempo para eliminar compuestos energéticos de entornos contaminados
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962384A (en) * 1972-04-10 1976-06-08 Hoffmann-La Roche Inc. Spray-drying technique for preparing agglomerated powders
CH586568A5 (enExample) * 1972-04-10 1977-04-15 Hoffmann La Roche
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE421042B (sv) * 1976-06-29 1981-11-23 Kockums Chem Sett att minska den for en viss biologisk effekt erforderliga mengden biologiskt aktiv substans
US4360061A (en) 1980-04-03 1982-11-23 Exxon Research And Engineering Co. Oil recovery process using polymer microemulsion complexes
US4353806A (en) 1980-04-03 1982-10-12 Exxon Research And Engineering Company Polymer-microemulsion complexes for the enhanced recovery of oil
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
FR2594693B1 (fr) * 1986-02-24 1990-01-05 Farah Nabil Nouveaux procedes de preparation a partir d'emulsions seches de formes orales solides a liberation modifiee et retardee de leur principes actifs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
CA2108266C (en) 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
US5688761A (en) 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
US5435936A (en) 1993-09-01 1995-07-25 Colgate Palmolive Co. Nonaqueous liquid microemulsion compositions
ES2094688B1 (es) * 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same

Also Published As

Publication number Publication date
US6280770B1 (en) 2001-08-28
EP1104290B1 (en) 2010-03-31
AU5486899A (en) 2000-03-06
CA2339991C (en) 2007-01-02
DE69942205D1 (de) 2010-05-12
EP2127642A2 (en) 2009-12-02
EP2127642A3 (en) 2010-02-24
ES2341510T3 (es) 2010-06-21
EP1104290A1 (en) 2001-06-06
CA2339991A1 (en) 2000-02-24
ATE462417T1 (de) 2010-04-15
JP2002522473A (ja) 2002-07-23
WO2000009093A1 (en) 2000-02-24
EP1104290A4 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
JP4815053B2 (ja) 経口投与の固形投与形態物としてのマイクロエマルション
JP2002522473A5 (enExample)
US6692771B2 (en) Emulsions as solid dosage forms for oral administration
Dobetti Fast-melting tablets: Developments and technologies
TWI241188B (en) Sertraline salts and sustained-release dosage forms of sertraline
JP4901469B2 (ja) 生物学的利用能および／または溶解度を増大させるための含浸粉末とその製造方法
AU703950B2 (en) Hydrophobic drug delivery systems
EP2471518B1 (en) Composition comprising oil drops
BRPI0513904B1 (pt) forma farmacêutica de multipartícula para substâncias ativas de baixa solubilidade e um processo para preparar a forma farmacêutica
FR2568472A1 (fr) Preparations pharmaceutiques retard et procede pour les fabriquer
CZ286051B6 (cs) Farmaceutický prostředek a způsob jeho použití pro dasažení projímavého účinku
JP2006510731A (ja) 標的化送達
JPS6230965B2 (enExample)
CN1726909A (zh) 丁苯酞自乳化释药体系及其制备方法和应用
EP1128826B1 (en) Chromone enteric release formulation
JPH0354926B2 (enExample)
JPH0115A (ja) 吸収改善製剤
CN1261273A (zh) 舍曲林的缓释剂型
CA2735660C (en) Dosage forms for weakly ionizable compounds
JP5684440B2 (ja) 組成物および固形製剤
AU2001241730A1 (en) Emulsions as solid dosage forms for oral administration
CN102697764A (zh) 一种含有异硫氰酸苯乙酯的肠溶固体制剂
A. Rahman et al. Self-emulsifying pellets prepared by extrusion/spheronization: in vitro/in vivo evaluation
CN1927202B (zh) 维生素e烟酸酯微囊及其制备方法
KR100587165B1 (ko) 알렌드로네이트 연질캡슐제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040204

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100927

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110816

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110829

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140902

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees